Neoadjuvant cisplatin-based chemotherapy in "primary" and "secondary" muscle-invasive bladder cancer-is it a surrogate for molecular subtypes?
Transl Cancer Res
.
2019 Mar;8(Suppl 2):S176-S179.
doi: 10.21037/tcr.2019.01.05.
Authors
Tibor Szarvas
1
2
,
Csilla Olah
2
,
Henning Reis
3
Affiliations
1
Department of Urology, University Hospital Essen, West German Cancer Center, University of Duisburg-Essen, Essen, Germany.
2
Department of Urology, Semmelweis University, Budapest, Hungary.
3
Institute of Pathology, University Hospital Essen, West German Cancer Center, University of Duisburg-Essen, Essen, Germany.
PMID:
35117093
PMCID:
PMC8797631
DOI:
10.21037/tcr.2019.01.05
No abstract available
Publication types
Editorial
Comment